Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Novel mechanism of action of Anfibatide: an anti-thrombotic agent targeting platelet GPIba

EF 2018-19

Résumé
Platelets play essential roles in maintaining hemostasis by adhering to vessel walls, activating, and aggregating. However, the same processes can result in vessel occlusion, which may lead to heart attack and stroke. Prior to vessel occlusion, shear stress at the stenotic area escalates. Here, interactions between the glycoprotein (GP) Ib-IX-V complex on platelet surfaces with von Willebrand factor on the injured vessel walls, play a key role in initiating platelet adhesion – making it a desirable target for novel anti-thrombotic therapies. Previous studies have demonstrated that integrin alphaIIbbeta3 inhibitors (the most abundant platelet adhesion receptor) although effective anti-thrombotic agents, can induce severe bleeding in some patients. Previously, our lab showed that Anfibatide (Anf) – a novel GPIbalpha antagonist – is a potent and safe anti-thrombotic agent. Recently, we observed that at high doses, Anf decreased platelet counts to almost half of initial levels. Interestingly, platelet levels rebounded and recovered to normal at 24 hours. This drug-induced “pseudo thrombocytopenia” has never been reported but understanding this mechanism – which may enhance the anti-thrombotic effect of Anf – is important for the development of Anf as an anti-thrombotic drug. We will assess sequestration of platelets in major organs following Anf delivery. Furthermore, we will assess changes on the surface adhesion molecules of platelets and its thrombogenic capacity following Anf delivery. The results of this project will shed light on the phenomena of platelet sequestration and expand our understanding of the mechanism of action of Anf – ultimately leading to the development of more effective pharmaceutical agents for the treatment of thrombotic cardiovascular diseases.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406639
Name
Ni Tiffany
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel mechanism of action of Anfibatide: an anti-thrombotic agent targeting platelet GPIba
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Platelet; Anti-Thrombotic; Gpibalpha Antagonist; Platelet; Shear Stress; Thrombocytopenia; Thrombus
Abstract
Platelets play essential roles in maintaining hemostasis by adhering to vessel walls, activating, and aggregating. However, the same processes can result in vessel occlusion, which may lead to heart attack and stroke. Prior to vessel occlusion, shear stress at the stenotic area escalates. Here, interactions between the glycoprotein (GP) Ib-IX-V complex on platelet surfaces with von Willebrand factor on the injured vessel walls, play a key role in initiating platelet adhesion – making it a desirable target for novel anti-thrombotic therapies. Previous studies have demonstrated that integrin alphaIIbbeta3 inhibitors (the most abundant platelet adhesion receptor) although effective anti-thrombotic agents, can induce severe bleeding in some patients. Previously, our lab showed that Anfibatide (Anf) – a novel GPIbalpha antagonist – is a potent and safe anti-thrombotic agent. Recently, we observed that at high doses, Anf decreased platelet counts to almost half of initial levels. Interestingly, platelet levels rebounded and recovered to normal at 24 hours. This drug-induced “pseudo thrombocytopenia” has never been reported but understanding this mechanism – which may enhance the anti-thrombotic effect of Anf – is important for the development of Anf as an anti-thrombotic drug. We will assess sequestration of platelets in major organs following Anf delivery. Furthermore, we will assess changes on the surface adhesion molecules of platelets and its thrombogenic capacity following Anf delivery. The results of this project will shed light on the phenomena of platelet sequestration and expand our understanding of the mechanism of action of Anf – ultimately leading to the development of more effective pharmaceutical agents for the treatment of thrombotic cardiovascular diseases.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ni, Tiffany
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~